- Home
- VTN vs DERM Comparison
VTN vs DERM Comparison
Compare VTN & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTN
- DERM
- Stock Information
- Founded
- VTN 1992
- DERM 2014
- Country
- VTN United States
- DERM United States
- Employees
- VTN N/A
- DERM N/A
- Industry
- VTN Finance Companies
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- VTN Finance
- DERM Health Care
- Exchange
- VTN Nasdaq
- DERM Nasdaq
- Market Cap
- VTN 151.5M
- DERM 165.6M
- IPO Year
- VTN N/A
- DERM 2021
- Fundamental
- Price
- VTN $10.43
- DERM $7.45
- Analyst Decision
- VTN
- DERM Strong Buy
- Analyst Count
- VTN 0
- DERM 3
- Target Price
- VTN N/A
- DERM $12.67
- AVG Volume (30 Days)
- VTN 41.7K
- DERM 218.4K
- Earning Date
- VTN 01-01-0001
- DERM 08-12-2025
- Dividend Yield
- VTN 3.74%
- DERM N/A
- EPS Growth
- VTN N/A
- DERM N/A
- EPS
- VTN 0.16
- DERM N/A
- Revenue
- VTN N/A
- DERM $56,397,000.00
- Revenue This Year
- VTN N/A
- DERM $28.10
- Revenue Next Year
- VTN N/A
- DERM $53.84
- P/E Ratio
- VTN $67.06
- DERM N/A
- Revenue Growth
- VTN N/A
- DERM N/A
- 52 Week Low
- VTN $8.49
- DERM $3.54
- 52 Week High
- VTN $10.81
- DERM $8.90
- Technical
- Relative Strength Index (RSI)
- VTN 63.88
- DERM 54.92
- Support Level
- VTN $10.08
- DERM $6.88
- Resistance Level
- VTN $10.26
- DERM $7.12
- Average True Range (ATR)
- VTN 0.10
- DERM 0.28
- MACD
- VTN 0.03
- DERM -0.01
- Stochastic Oscillator
- VTN 97.73
- DERM 80.23
About VTN Invesco Trust for Investment Grade New York Municipals
Invesco Trust For Investment Grade New York Municipals is a diversified closed-end management investment company. Its objective is to provide common shareholders with a high level of current income exempt from federal as well as from New York State and New York City income taxes, consistent with preservation of capital.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.